idarucizumab - Articles and news items

Boehringer Ingelheim logo

Antidote for rapid reversal of Pradaxa® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients

Industry news / 22 May 2014 / Boehringer Ingelheim

Boehringer Ingelheim announces the next step in the clinical development of idarucizumab, the investigational antidote for rapid reversal of dabigatran-induced anticoagulation…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+